Surgical Innovations Group plc

AIM:SUN Stock Report

Market Cap: UK£5.1m

Surgical Innovations Group Management

Management criteria checks 3/4

Surgical Innovations Group's CEO is David Marsh, appointed in Feb 2019, has a tenure of 5.83 years. total yearly compensation is £219.00K, comprised of 94.1% salary and 5.9% bonuses, including company stock and options. directly owns 3.38% of the company’s shares, worth £173.59K. The average tenure of the management team and the board of directors is 3.9 years and 11.5 years respectively.

Key information

David Marsh

Chief executive officer

UK£219.0k

Total compensation

CEO salary percentage94.1%
CEO tenure5.8yrs
CEO ownership3.4%
Management average tenure3.9yrs
Board average tenure11.5yrs

Recent management updates

Recent updates

Surgical Innovations Group plc (LON:SUN) Shares Fly 63% But Investors Aren't Buying For Growth

Jul 11
Surgical Innovations Group plc (LON:SUN) Shares Fly 63% But Investors Aren't Buying For Growth

Surgical Innovations Group plc's (LON:SUN) Share Price Is Matching Sentiment Around Its Revenues

Apr 19
Surgical Innovations Group plc's (LON:SUN) Share Price Is Matching Sentiment Around Its Revenues

Investors Don't See Light At End Of Surgical Innovations Group plc's (LON:SUN) Tunnel And Push Stock Down 33%

Dec 29
Investors Don't See Light At End Of Surgical Innovations Group plc's (LON:SUN) Tunnel And Push Stock Down 33%

Returns On Capital At Surgical Innovations Group (LON:SUN) Paint A Concerning Picture

Sep 07
Returns On Capital At Surgical Innovations Group (LON:SUN) Paint A Concerning Picture

Surgical Innovations Group (LON:SUN) Has Some Difficulty Using Its Capital Effectively

May 26
Surgical Innovations Group (LON:SUN) Has Some Difficulty Using Its Capital Effectively

Is Surgical Innovations Group (LON:SUN) Weighed On By Its Debt Load?

Jun 15
Is Surgical Innovations Group (LON:SUN) Weighed On By Its Debt Load?

Is Surgical Innovations Group (LON:SUN) Weighed On By Its Debt Load?

Sep 24
Is Surgical Innovations Group (LON:SUN) Weighed On By Its Debt Load?

Health Check: How Prudently Does Surgical Innovations Group (LON:SUN) Use Debt?

Mar 29
Health Check: How Prudently Does Surgical Innovations Group (LON:SUN) Use Debt?

CEO Compensation Analysis

How has David Marsh's remuneration changed compared to Surgical Innovations Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-UK£622k

Mar 31 2024n/an/a

-UK£565k

Dec 31 2023UK£219kUK£206k

-UK£509k

Sep 30 2023n/an/a

-UK£302k

Jun 30 2023n/an/a

-UK£96k

Mar 31 2023n/an/a

UK£84k

Dec 31 2022UK£211kUK£198k

UK£264k

Sep 30 2022n/an/a

-UK£56k

Jun 30 2022n/an/a

-UK£376k

Mar 31 2022n/an/a

-UK£416k

Dec 31 2021UK£201kUK£187k

-UK£456k

Sep 30 2021n/an/a

-UK£635k

Jun 30 2021n/an/a

-UK£815k

Mar 31 2021n/an/a

-UK£2m

Dec 31 2020UK£175kUK£162k

-UK£3m

Sep 30 2020n/an/a

-UK£4m

Jun 30 2020n/an/a

-UK£5m

Mar 31 2020n/an/a

-UK£4m

Dec 31 2019UK£186kUK£173k

-UK£3m

Sep 30 2019n/an/a

-UK£1m

Jun 30 2019n/an/a

UK£300k

Mar 31 2019n/an/a

UK£513k

Dec 31 2018UK£161kUK£122k

UK£725k

Sep 30 2018n/an/a

UK£521k

Jun 30 2018n/an/a

UK£317k

Mar 31 2018n/an/a

UK£403k

Dec 31 2017UK£126kUK£51k

UK£488k

Compensation vs Market: David's total compensation ($USD275.38K) is about average for companies of similar size in the UK market ($USD348.94K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Marsh (60 yo)

5.8yrs

Tenure

UK£219,000

Compensation

Mr. David John Marsh has been the Chief Executive Officer of Surgical Innovations Group plc since February 28, 2019. Mr. Marsh served as the Group Commercial Director at Surgical Innovations Group plc on t...

Leadership Team

NamePositionTenureCompensationOwnership
David Marsh
CEO & Director5.8yrsUK£219.00k3.38%
£ 173.6k
Christopher Martin
CFO & Executive Directorless than a yearno datano data
Alex Hogg
Operations Director5.8yrsno datano data
Stephen Seed
Chief Compliance Officerno datano datano data
Julia Taylor
HR Director1.4yrsno datano data
Damian Donnelly
Chief Commercial Officer3.9yrsno datano data

3.9yrs

Average Tenure

Experienced Management: SUN's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Marsh
CEO & Director7.3yrsUK£219.00k3.38%
£ 173.6k
Christopher Martin
CFO & Executive Directorless than a yearno datano data
Jonathan Glenn
Senior Independent Non-Executive Director & Chairman1.6yrsUK£24.00k0.14%
£ 7.2k
Michael McMahon
Member of Clinical Advisory Boardno dataUK£19.00kno data
Ian Brayshaw
Member of the Clinical Advisory Boardno datano datano data
Philippe Grange
Member of the Clinical Advisory Boardno datano datano data
Keyvan Djamarani
Independent Non-executive Directorless than a yearUK£2.00kno data
Marco Adamo
Member of the Clinical Advisory Board13.9yrsno datano data
James Halstead
Member of the Clinical Advisory Board12.9yrsno datano data
Chris Sutton
Member of the Clinical Advisory Board12.9yrsno datano data
John Griffith
Member of the Clinical Advisory Board12yrsno datano data
Henrik Steinbrecher
Member of the Clinical Advisory Board11.5yrsno datano data

11.5yrs

Average Tenure

60yo

Average Age

Experienced Board: SUN's board of directors are seasoned and experienced ( 11.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:37
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Surgical Innovations Group plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce PackardCantor Fitzgerald Europe
Michael MitchellPanmure Liberum Historic (Panmure Gordon)
Bruce PackardSeymour Pierce Limited